James A Shayman

USPTO Granted Patents = 26 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 2.6

ph-index = 17

Forward Citations = 690(Granted Patents)

Company Filing History:

26 out of 3,381

University of Michigan

where one patent can have more than one assignee

Years Active: 1994-2022

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11220479 - Glucosylceramide synthase inhibitors and therapeutic methods using the same (2022-01-11),

2. 10202340 - Glucosylceramide synthase inhibitors and therapeutic methods using the same (2019-02-12),

3. 10111937 - Method of reducing accumulation of intracellular tingible body macrophages (2018-10-30),

4. 9309553 - Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus (2016-04-12),

5. 8961959 - Glucosylceramide synthase inhibitors and therapeutic methods using the same (2015-02-24),

6. 8052970 - Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis (2011-11-08),

7. 7615573 - Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors (2009-11-10),

8. 7582442 - Methods and compositions for using aleveolar macrophage phospholipase A2 (2009-09-01),

9. 7335681 - Amino ceramide-like compounds and therapeutic methods of use (2008-02-26),

10. 7319015 - Methods and compositions for using alveolar macrophage phospholipase A2 (2008-01-15),

11. 7253185 - Amino ceramide-like compounds and therapeutic methods of use (2007-08-07),

12. 7196205 - [object Object] (2007-03-27),

13. 7148251 - Amino ceramide-like compounds and therapeutic methods of use (2006-12-12),

14. 6916802 - Amino ceramide-like compounds and therapeutic methods of use (2005-07-12),

15. 6890949 - Amino ceramide-like compounds and therapeutic methods of use (2005-05-10),

Title: Innovations of James A. Shayman: Advancements in Glycosphingolipid Research

Introduction

James A. Shayman, based in Ann Arbor, MI, is a prominent figure in the field of biomedical research, holding an impressive portfolio of 26 patents. His work primarily focuses on glucosylceramide synthase inhibitors and their therapeutic applications, particularly in treating complex diseases such as Gaucher disease and Fabry disease.

Latest Patents

Shayman's latest patents include significant advancements in glucosylceramide synthase inhibitors and the therapeutic methods associated with them. His patents disclose compositions that inhibit glucosylceramide synthase, providing valuable treatment options for diseases wherein these inhibitors offer clinical benefits. These innovations represent a critical step forward in addressing metabolic disorders and enhancing patient care.

Career Highlights

Over the course of his career, James A. Shayman has made substantial contributions to the field of drug development and biomedical research. He has held notable positions at the University of Michigan, where he conducted pivotal research, as well as at Genzyme Corporation, enhancing the translation of his discoveries into practical therapeutic solutions. Shayman's commitment to innovation has driven advancements in understanding and treating severe genetic disorders.

Collaborations

Throughout his career, Shayman has collaborated with several esteemed colleagues, including Norman S. Radin and Akira Abe. These partnerships have further enriched his research, bringing together diverse expertise and fostering a collaborative approach to scientific discovery.

Conclusion

James A. Shayman stands out as a leading inventor in the realm of medical research, particularly with his focus on glucosylceramide synthesis and related therapeutic methods. His extensive patent portfolio and collaborative efforts underscore his dedication to advancing treatment options for complex diseases. Through his innovations, Shayman continues to make a lasting impact on the field and improve the lives of those affected by metabolic disorders.

This text is generated by artificial intelligence and may not be accurate.